SOPA Images via Getty Images
The EMA has started the examination (in “rolling review”) of the Vero Cell vaccine developed by the Chinese Sinovac. This was announced by the European Agency on Twitter. The EU applicant is the Italian Life’On srl, based in Pomezia.
“The Committee’s decision to initiate the rolling review is based on the preliminary results of laboratory studies (non-clinical data) and clinical studies. These studies suggest that the vaccine triggers the production of antibodies that target Sars-Cov-2, the virus that causes Covid-19, and may help protect against the disease, ”the EMA wrote in a statement.
The EMA will further communicate when the marketing authorization application for the vaccine has been submitted.
It is the first Chinese vaccine on which Ema starts the analysis. Sinovac has shown an efficacy rate between 50% and 90% in different studies and is currently licensed for use in China, Indonesia, Brazil and Turkey. The company said 200 million doses have already been delivered worldwide and is in the process of doubling its production capacity to 2 billion doses per year.